Evidence map›Paper›PMID 40284449›Full record

ArticlePharmaceutics2025

Microfluidic Optimization of PEI-Lipid Hybrid Nanoparticles for Efficient DNA Delivery and Transgene Expression.

Mahboubeh Hosseini-Kharat, Anthony Wignall, Zelalem A Mekonnen, Ben S-Y Ung, Bradley Chereda, Kristen E Bremmell, Branka Grubor-Bauk, Clive A Prestidge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mahboubeh Hosseini-KharatClinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-5099-2712
Anthony WignallClinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.
Zelalem A MekonnenViral Immunology Group, Basil Hetzel Institute for Translational Health Research, Adelaide Medical School, University of Adelaide, Woodville South, SA 5011, Australia.ORCID 0000-0002-3705-4526
Ben S-Y UngQuality Use of Medicines and Pharmacy Research Centre, University of South Australia City East Campus, Frome Rd., Adelaide, SA 5000, Australia.ORCID 0000-0001-7667-3648
Bradley CheredaCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA 5000, Australia.ORCID 0000-0003-4421-0424
Kristen E BremmellClinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0002-7633-0562
Branka Grubor-BaukViral Immunology Group, Basil Hetzel Institute for Translational Health Research, Adelaide Medical School, University of Adelaide, Woodville South, SA 5011, Australia.ORCID 0000-0002-4642-105X
Clive A PrestidgeClinical and Health Sciences, Centre for Pharmaceutical Innovation, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-5401-7535

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

DNA deliverygene therapyGFP expressionlipid nanoparticles (LNPs)lipid-polymer hybrid systemsluciferase assaysmicrofluidic mixingpolyethyleneimine (PEI)transgene expression

Identifiers

PMID40284449
PMCPMC12030462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.